Metabolic testing rates in 3 state medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs

Archives of General Psychiatry

Volumn 67, Issue 1, 2010, Pages 17-24

  Morrato, Elaine H ^a,b,c   Druss, Benjamin ^d   Hartung, Daniel M ^e   Valuck, Robert J ^c   Allen, Richard ^f   Campagna, Elizabeth ^c   Newcomer, John W ^g  

^a Children's Hospital Colorado   (United States)

^b Global Health and Health Disparities   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d EMORY UNIVERSITY   (United States)

^e OREGON STATE UNIVERSITY   (United States)

^f Peak Statistical Services   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; FLUOXETINE; GLUCOSE; LIPID; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SALBUTAMOL; ZIPRASIDONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICAL SOCIETY; PRESCRIPTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; CALIFORNIA; CHILD; DIABETES MELLITUS; DRUG LABELING; DYSLIPIDEMIAS; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; LIPIDS; MALE; MEDICAID; MENTAL DISORDERS; MIDDLE AGED; MISSOURI; PSYCHOTIC DISORDERS; SOCIETIES, MEDICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 73649122825     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2009.179     Document Type: Article

References (32)

1. Rosack J. FDA to require diabetes warning on antipsychotics. Psychiatric News. 2003;38:1.
2. Show 28: warning about hyperglycemia and atypical antipsychotic drugs [webcast]. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/transcript.cfm? show=28. FDA Safety News. June, 2004.
3. Janssen Pharmaceutica Inc. Risperdal (risperidone) revised label. Washington, DC: US Food and Drug Administration, Medwatch; 2003.
4. Pfizer. Geodon (ziprasidone): Dear Healthcare Practitioner letter, August 2004. http://www.fda.gov/Safety/MedWatch/SafetyInformation / SafetyAlertsforHumanMedicalProducts/ucm154977.htm#. Accessed November 28, 2005.
5. American Diabetes Association, American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65(2):267-272.
6. Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA. 2007;298(15):1794-1796.
7. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT Jr, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S. Physical health monitoring of patients with schizophrenia.AmJ Psychiatry. 2004;161(8):1334-1349.
8. van Winkel R, van Os J, Celic I, Van Eyck D, Wampers M, Scheen A, Peuskens J, De Hert M. Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program. J Clin Psychiatry. 2008;69(8):1319-1327.
9. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1-93.
10. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19-32.
11. Goff DC, Cather C, Evins AE, Henderson DC, Freudenreich O, Copeland PM, Bierer M, Duckworth K, Sacks FM. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry. 2005;66(2):183-194.
12. Frayne SM, Halanych JH, Miller DR, Wang F, Lin H, Pogach L, Sharkansky EJ, Keane TM, Skinner KM, Rosen CS, Berlowitz DR. Disparities in diabetes care: impact of mental illness. Arch Intern Med. 2005;165(22):2631-2638.
13. Morrato EH, Newcomer JW, Allen RR, Valuck R. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J Clin Psychiatry. 2008;69(2):316-322.
14. Hsu C, Ried LD, Bengtson MA, Garman PM, McConkey JR, Rahnavard F. Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: findings from a Veterans Affairs-based population. J Am Pharm Assoc (2003). 2008;48(3):393-400.
15. Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents [published online ahead of print January 15, 2009]. Am J Psychiatry. 2009;166(3):345-353.
16. Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening before and after the ADA Consensus Statement on antipsychotic drugs and risk of diabetes and dyslipidemia [abstract]. Diabetes. 2008;57(suppl 1): A3946.
17. Zuvekas SH. Prescription drugs and the changing patterns of treatment for mental disorders, 1996-2001. Health Aff (Millwood). 2005;24(1):195-205.
18. Ma J, Vaillancourt R, Boddam R, Auger S, Sampalis J. Association between antidepressant use and prescribing of gastric acid suppressants. Can J Psychiatry. 2006;51(3):178-184.
19. Clinical classifications software (CCS) for ICD-9-CM fact sheet. Agency for Health-care Research and Quality, Healthcare Cost and Utilization Project (HCUP) Web site. http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccsfactsheet.jsp. Accessed August 1.
20. American Diabetes Association. Standards of medical care in diabetes: 2007. 2007; 30(suppl 1):S4-S41.
21. Rifas-Shiman SL, Forman J, Lane K, Caspard H, Gillman M. Diabetes and lipid screening among patients in primary care: a cohort study. BMC Health Serv Res. 2008;8:25.
22. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299-309.
23. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11(7):449-457.
24. Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Paper presented at: 26th Annual SAS Users Group International Conference; April 2001; Cary, NC.
25. Baser O. Too much ado about propensity score models? comparing methods of propensity score matching. Value Health. 2006;9(6):377-385.
26. Buckley PF, Miller DD, Singer B, Arena J, Stirewalt EM. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res. 2005; 79(2-3):281-288.
27. Suppes T, McElroy SL, Hirschfeld R. Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: a survey of 500 US psychiatrists. Psychopharmacol Bull. 2007;40(2):22-37.
28. Rogers EM. Diffusion of Innovations. 5th ed. New York, NY: Free Press; 2003.
29. Libby AM, Brent DA, Morrato EH, Orton HD, Allen R, Valuck RJ. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry. 2007;164(6):884-891.
30. Morrato EH, Libby AM, Orton HD, Degruy FV III, Brent DA, Allen R, Valuck RJ. Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry. 2008;165(1):42-50.
31. Ketter TA, Haupt DW. Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice. Curr Med Res Opin. 2006;22(12):2345-2353.
32. Druss BG, Marcus SC, Campbell J, Cuffel B, Harnett J, Ingoglia C, Mauer B. Medical services for clients in community mental health centers: results from a national survey. Psychiatr Serv. 2008;59(8):917-920.